ArticleScience (New York, N.Y.)2021
Prevalent, protective, and convergent IgG recognition of SARS-CoV-2 non-RBD spike epitopes.
Open access · hybridAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers.
0numbers the graph read from it
0cells of the map it votes in
193citing papers in PubMed
17.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
193 citing papers in PubMed, 289 citations in OpenAlex.
- Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines.Cell reports · 2025Trial
- Human memory T cell dynamics after aluminum-adjuvanted inactivated whole-virion SARS-CoV-2 vaccination.Scientific reports · 2023Trial
- Trial
- Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey.Lancet (London, England) · 2021Trial
- Article
- Structure-Based Adaptation of a SARS-CoV-2 Neutralizing Peptide to New Virus Variants.Journal of medicinal chemistry · 2026Article
- Structural and functional characterization of a conserved cryptic epitope on SARS-CoV-2 spike S2 subunit.PLoS pathogens · 2026Article
- Mass spectrometry-based mapping of conformational epitopes on SARS-CoV-2 antigens targeted by monoclonal antibodies.International journal of biological macromolecules · 2026Article
- Article
- Population-level genomic analysis of immunoglobulin loci variation in rhesus macaques reveals extensive germline diversity.Immunity · 2026Article
- The emergence of putative epistatic mutations and iSNVs in SARS-CoV-2 XBB.1.16 variants linked with alteration in immunogenic determinants.Frontiers in immunology · 2026Article
- Insertion outside the supersite in the N-terminal domain of the SARS-CoV-2 spike glycoprotein may contribute to evasion of neutralizing antibodies.Frontiers in microbiology · 2026Article
- Enhanced antibody response to the conformational non-RBD regionEmerging microbes & infections · 2025Article
- Review
- Optimization of VE607 to generate analogs with improved neutralization activities against SARS-CoV-2 variants.Journal of virology · 2025Article
- Insights from deep mutational scanning in the context of an emerging pathogen.Biochemical Society transactions · 2025Review
- Article
- Repertoire, function, and structure of serological antibodies induced by the R21/Matrix-M malaria vaccine.The Journal of experimental medicine · 2025Article
- Adaptive immune responses to SARS-CoV-2 in DMARD-treated patients with chronic inflammatory rheumatisms.RMD open · 2025Article
- SARS-CoV-2 spike protein: structure, viral entry and variants.Nature reviews. Microbiology · 2025Review
133 more citing papers are in PubMed but not listed here.
Corrections and comments
- Update of
Authors and funding
38 authors at 7 institutions in 1 country.
William N VossDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-4403-1939
Yixuan J Hou *Department of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0002-8323-7243
Nicole V Johnson *Department of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0003-4351-125X
George DelidakisDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-4330-9476
Jin Eyun KimDepartment of Biomedical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-6297-3292
Kamyab JavanmardiDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-6449-6709
Andrew P HortonDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-0272-4411
Foteini BartzokaDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Chelsea J ParesiDepartment of Chemistry, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-2405-8085
Yuri TannoDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-1868-7168
Chia-Wei ChouDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-9618-338X
Shawn A AbbasiU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.ORCID 0000-0002-7516-5876
Whitney PickensDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Katia GeorgeDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-8511-7918
Daniel R BoutzDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-7462-4105
Dalton M TowersDepartment of Chemical Engineering, The University of Texas at Austin, Austin, TX, USA.
Jonathan R McDanielBiomedicine Design, Pfizer, Cambridge, MA, USA.ORCID 0000-0001-8575-3535
Daniel BillickDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-5002-7699
Jule GoikeDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
Lori RoweBiotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0003-3744-496X
Dhwani BatraBiotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Jan PohlBiotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Justin LeeBiotechnology Core Facility Branch, Division of Scientific Resources, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0002-6539-2637
Shivaprakash GangappaImmunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Suryaprakash SambharaImmunology and Pathogenesis Branch, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.ORCID 0000-0002-4715-5793
Michelle GadushCenter for Biomedical Research Support, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-1705-7076
Nianshuang WangDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-7569-011X
Maria D PersonCenter for Biomedical Research Support, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-8161-9339
Brent L IversonDepartment of Chemistry, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0001-7974-3605
Jimmy D GolliharDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.
John M DyeU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.ORCID 0000-0002-0883-5016
Andrew S HerbertU.S. Army Medical Research Institute of Infectious Diseases, Frederick, MD, USA.ORCID 0000-0003-4697-7928
Ilya J FinkelsteinDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-9371-2431
Ralph S BaricDepartment of Epidemiology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID 0000-0001-6827-8701
Jason S McLellanDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0003-3991-542X
George GeorgiouDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA.ORCID 0000-0002-8823-3073
Jason J LavinderDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA. jlavinder@utexas.edu gci@utexas.edu.ORCID 0000-0001-6044-1332
Gregory C IppolitoDepartment of Molecular Biosciences, The University of Texas at Austin, Austin, TX, USA. jlavinder@utexas.edu gci@utexas.edu.ORCID 0000-0002-7565-7002
The University of Texas at Austin · USCenters for Disease Control and Prevention · USUnited States Army Medical Research Institute of Infectious Diseases · USHouston Methodist · USUniversity of North Carolina at Chapel Hill · USPfizer (United States) · USTulane University · US
Funding
Collaborative Influenza Vaccine Innovation Centers (CIVICs): Component A: Vaccine Center75N93019C00050 · NIAID · DUKE UNIVERSITY · PI MOODY, TONY · 2019 to 2025
$69.1MProject 3: Serological Interactions with the Mucosal Innate Immune System Regulates COVID-19 Associated Tissue Damage.U54CA260543 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BARIC, RALPH S · 2020 to 2024
$9.8MResource for Biocomputing Visualization and InformaticsP41GM103311 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2012 to 2017
$8.2MStructure, Function and Antigenicity of Coronavirus Spike ProteinsR01AI127521 · NIAID · UNIVERSITY OF TEXAS AT AUSTIN · PI MCLELLAN, JASON SCOTT, WARD, ANDREW BARRETT · 2017 to 2021
$3.1MNCI NIH HHS U54 CA260543NIAID NIH HHS 75N93019C00050NIAID NIH HHS R01 AI127521NIGMS NIH HHS P41 GM103311
Abstract
The molecular composition and binding epitopes of the immunoglobulin G (IgG) antibodies that circulate in blood plasma after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are unknown. Proteomic deconvolution of the IgG repertoire to the spike glycoprotein in convalescent subjects revealed that the response is directed predominantly (>80%) against epitopes residing outside the receptor binding domain (RBD). In one subject, just four IgG lineages accounted for 93.5% of the response, including an amino (N)-terminal domain (NTD)-directed antibody that was protective against lethal viral challenge. Genetic, structural, and functional characterization of a multidonor class of "public" antibodies revealed an NTD epitope that is recurrently mutated among emerging SARS-CoV-2 variants of concern. These data show that "public" NTD-directed and other non-RBD plasma antibodies are prevalent and have implications for SARS-CoV-2 protection and antibody escape.
Indexed as
AnimalsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralAntibody AffinityCOVID-19EpitopesHumansImmune EvasionImmunoglobulin GImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionMiceMice, Inbred BALB CMutationProtein DomainsAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralEpitopesImmunoglobulin GImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.